These results support the use of inhibitors of the ATX/LPA/LPARs axis in the treatment of fibrotic disorders, as addressed in numerous clinical trials, mainly in idiopathic pulmonary fibrosis and scleroderma. The gene discussed is ENPP2; the disease is pulmonary fibrosis.